UFPT · UFP Technologies, Inc.

Current Thesis

UFP Technologies' medical-outsourcing recovery case requires a weekly reclaim of the former $300 shelf before a weekly close below $273 ends it. This is a new, low-conviction recovery hypothesis: the previously published $288.79 weekly invalidation threshold was breached by the 2026-09-18 adjusted close of $276.69. The earlier case has failed; the lower threshold does not preserve it.

The post-Q2 narrative is dead — that is the structural inference from the 2026-09-18 close below both the September 4 reference close and the former $300 shelf. The operating record remains stronger than the price structure: the August 3 release reported Q2 organic growth of 12.4%. Q2 earnings release

A company release dated 2026-09-09 disclosed the acquisition of CI Medical, a medical-device precision-printing business. It supplied no purchase price, acquired revenue or earnings contribution, so the acquisition cannot yet support a quantified earnings upgrade. CI Medical release

Bullish and bearish views on UFP Technologies, Inc.

The model's bull view on UFP Technologies, Inc. (UFPT), in brief: Organic growth accelerated in Q2. The 2026-08-03 release reported Q2 sales of $174.0 million, up 15.1%, and organic growth of 12.4%, compared with first-half organic growth of 6.8%. These are reported results, not a forecast of persistence. Q2 earnings release Growth extended… The bear view: The prior threshold has failed. The 2026-09-18 adjusted close of $276.69 was below the published $288.79 weekly threshold. The supplied adjusted series places the shares 17.4% below their $334.84 52-week high as of September 18. Capacity benefits are taking longer. In the… Both cases follow in full.

Bull Case

• Organic growth accelerated in Q2. The 2026-08-03 release reported Q2 sales of $174.0 million, up 15.1%, and organic growth of 12.4%, compared with first-half organic growth of 6.8%. These are reported results, not a forecast of persistence. Q2 earnings release
• Growth extended beyond major customers. In the same August 3 release, management reported Q2 growth of 14.7% among the top five customers and 19.7% across the remaining medical-technology business. That supports breadth within the reported quarter; it does not establish a durable trend. Q2 earnings release
• Acquisition adds a manufacturing capability. The release dated 2026-09-09 identifies CI Medical's expertise in printing on difficult medical-device substrates. The capability is documented; the financial benefit remains undisclosed. Company announcement

Bear Case

• The prior threshold has failed. The 2026-09-18 adjusted close of $276.69 was below the published $288.79 weekly threshold. The supplied adjusted series places the shares 17.4% below their $334.84 52-week high as of September 18.
• Capacity benefits are taking longer. In the 2026-08-03 release, management said Dominican Republic investment benefits were taking longer than anticipated and described near-term mix and margin pressure in US operations. This qualifies the expansion story despite Q2 gross margin of 29.3%. Management commentary
• A recent valuation revision declined. Argus's quantitative report dated 2026-09-09 lowered its UFPT price target to $317. That is a third-party valuation revision, not evidence of improving company orders. Argus report listing

Setup & Price Structure

The September 18 adjusted price snapshot shows a three-month gain of 18.6% and a 14-period relative strength index (RSI) of 20.4. Positive trailing performance and weak recent momentum coexist; neither establishes a reversal. A current moving-average value is missing, so distance from a rising average cannot be stated.

Public daily history records intraday lows of $273.00 on 2026-09-15 and 2026-09-18. Those observations provide a dated reference for the recovery hypothesis, but the sample is too small to establish a durable base. A weekly close above the former $300 shelf defines the recovery outcome; a weekly close below $273 invalidates it first. Daily price history

Positioning evidence remains limited. The Form 4 filed 2026-08-27 disclosed director Marc Kozin's August 25 sales at $303.58–$305.41. This establishes insider supply on that date, not the cause of September weakness. The August 4 Benzinga movers coverage documents attention around earnings, but that isolated coverage does not establish retail crowding.

Catalyst Calendar (next 30 days)

• 2026-09-30 — Q3 period ends. This is an accounting milestone, not a results announcement. No company-confirmed earnings release or investor event within the next 30 days was identified on the company's calendar as of 2026-09-20. Company news and events
• ~2026-11-02, est. Q3 results. MarketBeat identifies this as an estimated date and explicitly says the company has not confirmed it. This later event matters because it can test organic-growth persistence and disclose acquisition economics; acquired revenue alone would not confirm organic acceleration. Earnings calendar

What Would Change Our Mind

Failure of the September reference lows would end the provisional recovery case: a weekly close below $273 would breach the intraday lows recorded on September 15 and September 18. The former $288.79 invalidation has already occurred and remains a failed forecast on the record. Price history

A weekly close above $300 before that breach would establish the defined price recovery. Fundamental confidence would require a separate operating test: Q3 organic growth below the first-half 2026 rate of 6.8% would contradict the acceleration argument. Management's 2026-08-24 presentation described growth and margin targets over three to five years, so those targets cannot substitute for the next quarterly result.

Correlation Notes

This remains a single-name recovery case. The August 3 release reported growth across medical customers while non-medical business was flat, supporting a medical-demand exposure rather than a broad industrial explanation. Q2 release No paired sector-return series accompanies the September 18 observations, so a measured sector correlation or group-led recovery claim is unsupported.